靶向测序识别深静脉血栓形成的新遗传风险因素:一项734个基因的研究
研究纳入899例深静脉血栓(DVT)患者和599例对照,对734个止血相关基因编码区进行靶向测序,发现F5、ABO、FGA-FGG和CYP4V2-KLKB1-F11的常见变异与DVT风险相关,未发现罕见变异负荷与DVT风险的关联。
要点
- 3617个常见变异中62个与DVT风险相关(FDR<0.10),多数位于F5、ABO、FGA-FGG和CYP4V2-KLKB1-F11。
- F5先导变异rs6672595的OR为1.58(95%CI 1.29-1.92),与已知变异rs4524呈中度连锁。
- KLKB1错义变异rs3733402在条件于已知变异后仍与DVT相关(OR 1.36,95%CI 1.10-1.69)。
核心结论
- 研究确认了DVT与F5、ABO、FGA-FGG和CYP4V2-KLKB1-F11常见变异的关联,并观察到F5和CYP4V2-KLKB1-F11的次要信号,需在更大规模研究中重复和精细定位。
研究设计与样本
- 纳入来自三项病例对照研究(DVT-Milan、MEGA和THE-VTE)的899例DVT患者和599例对照,对734个止血相关基因的编码区进行靶向DNA测序。
- 对常见变异(MAF≥1%)进行单变异关联检验,对罕见变异(MAF≤1%)进行基于基因的检验,采用错误发现率(FDR)校正多重检验。
主要发现
- 3617个常见变异中62个与DVT风险相关(FDR<0.10),多数位于F5、ABO、FGA-FGG和CYP4V2-KLKB1-F11。
- F5先导变异rs6672595的OR为1.58(95%CI 1.29-1.92),与已知变异rs4524呈中度连锁;交互条件分析提示内含子变异可能驱动该关联。
- 在F11区域观察到次要关联:KLKB1错义变异rs3733402在条件于已知变异rs2039614和rs2289252后仍相关(OR 1.36,95%CI 1.10-1.69)。
- 在CBS和MASP1观察到两个新变异关联,但在INVENT联盟的荟萃分析数据中未重复。
- 不支持罕见变异负荷与DVT风险相关(FDR>0.2)。
局限性
- 在CBS和MASP1观察到的新变异关联未在INVENT联盟的荟萃分析数据中重复。
- F5和CYP4V2-KLKB1-F11的次要信号需在更大规模研究中重复和精细定位。
- 不支持罕见变异负荷与DVT风险相关(FDR>0.2)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Essentials Deep vein thrombosis (DVT) has a large unknown genetic component. We sequenced coding areas of 734 hemostasis-related genes in 899 DVT patients and 599 controls. Variants in F5, FGA-FGG, CYP4V2-KLKB1-F11, and ABO were associated with DVT risk. Associations in KLKB1 and F5 suggest a more complex genetic architecture than previously thought. SUMMARY: Background Although several genetic risk factors for deep vein thrombosis (DVT) are known, almost all related to hemostasis, a large genetic component remains unexplained. Objectives To identify novel genetic determinants by using targeted DNA sequencing. Patients/Methods We included 899 DVT patients and 599 controls from three case-control studies (DVT-Milan, Multiple Environmental and Genetic Assessment of risk factors for venous thrombosis [MEGA], and the Thrombophilia, Hypercoagulability and Environmental Risks in Venous Thromboembolism [THE-VTE] study) for sequencing of the coding regions of 734 genes involved in hemostasis or related pathways. We performed single-variant association tests for common variants (minor allele frequency [MAF] ≥ 1%) and gene-based tests for rare variants (MAF ≤ 1%), accounting for multiple testing by use of the false discovery rate (FDR). Results Sixty-two of 3617 common variants were associated with DVT risk (FDR < 0.10). Most of these mapped to F5,ABO,FGA-FGG, and CYP4V2-KLKB1-F11. The lead variant at F5 was rs6672595 (odds ratio [OR] 1.58, 95% confidence interval [CI] 1.29-1.92), in moderate linkage with the known variant rs4524. Reciprocal conditional analyses suggested that intronic variation might drive this association. We also observed a secondary association at the F11 region: missense KLKB1 variant rs3733402 remained associated conditional on known variants rs2039614 and rs2289252 (OR 1.36, 95% CI 1.10-1.69). Two novel variant associations were observed, in CBS and MASP1, but these were not replicated in the meta-analysis data from the International Network against Thrombosis (INVENT) consortium. There was no support for a burden of rare variants contributing to DVT risk (FDR > 0.2). Conclusions We confirmed associations between DVT and common variants in F5,ABO,FGA-FGG, and CYP4V2-KLKB1-F11, and observed secondary signals in F5 and CYP4V2-KLKB1-F11 that warrant replication and fine-mapping in larger studies.
引用
- de Haan HG, van Hylckama Vlieg A, Lotta LA, et al. Targeted sequencing to identify novel genetic risk factors for deep vein thrombosis: a study of 734 genes. J Thromb Haemost. 2018. PMID: 30168256. doi:10.1111/jth.14279
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。